#Canada #Quebec #inflammatory diseases #Devonian Health Group #ThinkEquity Conference

Devonian Health Group at ThinkEquity Conference

Quebec, October 22, 2025 – Devonian Health Group Inc. has announced its participation in the highly anticipated ThinkEquity Conference, which will take place at the prestigious Mandarin Oriental in New York City on October 30, 2025. Dr. André Boulet, PhD, Chairman and CEO of Devonian, is set to present at the conference, highlighting the company’s innovative approaches in the biopharmaceutical sector, particularly in the treatment of inflammatory diseases.

During this prestigious event, institutional investors and analysts will gather to engage with growth-oriented companies. It serves as a significant platform for networking and investment opportunities. Investors keen to meet with Devonian’s management are encouraged to register on the conference website to schedule personal meetings, fostering direct communication regarding Devonian’s future prospects and advancements.

Non-Brokered Private Placement Completion

In conjunction with the conference announcement, Devonian also reveals the successful closure of a non-brokered private placement that has raised total gross proceeds of approximately $334,500.33. This offering included the issuance of 1,967,649 units at a price of $0.17 each, where each unit comprises one common share and one share purchase warrant. The warrants provide investors with the option to purchase shares at the same price over a duration of 24 months post-issuance.

These funds will be vital in supporting Devonian's working capital needs and advancing its corporate overhead as well as research and development initiatives. It is noteworthy that finder's fees for the private placement amounted to $14,166.68. The units produced in this placement will be subject to a hold period, concluding on February 23, 2026, in accordance with Canadian securities regulations. The initiative remains pending final approval from the TSX Venture Exchange.

About Devonian Health Group

Devonian Health Group Inc. specializes in developing groundbreaking prescription medications aimed at addressing inflammatory diseases. The company’s mission is deeply rooted in innovation, aiming to provide effective solutions to patients while ensuring sustainable growth. For additional insights about the company, visit Devonian's official website.

Cautionary Statements

It's essential for stakeholders and interested parties to recognize that the company has made various forward-looking statements. These statements include expectations regarding the usage of proceeds from the private placement, the anticipated outcomes of the conference attendance, and corporate development plans. However, they are subject to inherent risks and uncertainties, and actual results could significantly differ due to various factors. Developers and management advise against placing undue reliance on these forward-looking remarks, acknowledging that the landscape remains unpredictable.

For further details and media inquiries, contact Devonian’s investor relations team. The company continues its commitment to transparency in its endeavors as it advances in the biopharmaceutical field.